Background. In resource-limited settings, genotype testing at virologic failure on first-line antiretroviral therapy (ART) may identify patients with wild-type (WT) virus. After adherence counseling, these patients may safely and effectively continue first-line ART, thereby delaying more expensive second-line ART.
considerably less expensive than PI-based ART [2] , although more likely to lead to viral resistance [3] .
In the United States and Europe, genotype testing to distinguish resistant and nonresistant (wild-type [WT] ) virus is the standard of care at ART initiation and failure [4] . In resourcelimited settings, public health approaches to ART emphasize algorithms that exclude genotype testing, likely due to concerns for the complexity of healthcare delivery, upfront test costs, and the absence of ART options [1] . Without genotype testing, persistent observed HIV viremia or perceived virologic failure (based on CD4 count) prompts a switch to second-line ART. However, patients who fail ART with WT virus often "fail" due to medication nonadherence rather than drug resistance. Genotype may distinguish patients with resistant virus, who merit a switch to PI-based ART, from patients with WT virus, who with effective adherence counseling might succeed on a renewed trial of first-line ART [4, 5] . Such management of patients with WT virus would defer a switch to second-line ART. We used a computer model to project the clinical impact, cost, and cost-effectiveness of genotype resistance testing at first-line ART failure in South Africa.
METHODS

Analytic Overview
Using a computer simulation model of HIV disease, we assessed clinical and cost-effectiveness outcomes of genotype testing among HIV-infected patients failing first-line NNRTIbased ART. We first simulated the period between ART initiation and first-line ART failure ("initialization cohort") to determine cohort characteristics at first-line ART failure. Next, in the "main analysis," we investigated 2 strategies: the current standard of care [6] (no genotype) and genotype testing at first-line ART failure (genotype). Two cohorts of patients were simulated for each strategy: those who failed first-line ART with WT virus ("No Geno WT" and "Geno WT") and those who failed with NNRTI-resistant virus ("No Geno Resistant" and "Geno Resistant"; Figure 1 ). Projected outcomes were time on PI-based second-line ART, life expectancy, and mean perperson lifetime costs, all from the time of first-line ART failure. Total cohort outcomes for genotype and no genotype strategies were calculated as the weighted average of No Geno WT and No Geno Resistant for no genotype and Geno WT and Geno Resistant for genotype, weighted in each case by the prevalence of resistant and WT virus at first-line ART failure.
In no genotype, at confirmed virologic failure all individuals switched immediately to PI-based second-line ART with lopinavir/ritonavir and 2 nucleoside reverse transcriptase inhibitors (NRTIs). In genotype, a genotype test was performed. Results informed clinical decisions as follows: (1) if the test result indicated WT virus (Geno WT), we modeled a continuation of NNRTI-based ART following a routine adherence intervention. If subsequent failure occurred, PI-based second-line ART was initiated; (2) if the test result indicated resistant virus (Geno Resistant), we modeled a switch to PIbased second-line ART. The efficacy of the PI-based regimen for each of the 4 modeled cohorts depended on the presence of WT or resistant virus (Figure 1 ). Because the acquisition of viral resistance to ART is often time-dependent [7] , we conservatively assumed a 5% decrement in the efficacy of ART for every 3 months of a genotype-associated delay in care (base case delay = 3 months; Supplementary Appendix).
Genotype was compared with no genotype using an incremental cost-effectiveness ratio (ICER) in 2010 US dollars (USD) per year of life saved ($/YLS). We adopted a modified societal perspective considering only HIV-associated direct costs. Future costs and life expectancy were discounted at 3% per year [8] . Following the general guidance of the WHO Figure 1 . Diagram for evaluation of genotype testing at first-line antiretroviral therapy (ART) failure. Two strategies for management of confirmed virologic failure after first-line ART failure are compared. The genotype strategy represents the implementation of drug resistance genotype testing at the time of first-line ART failure. In this strategy, the switch to protease inhibitor-based second-line ART is dependent on whether the test result indicates the presence of wild-type or resistant virus. The percentages reflect the proportion of the cohort with virologic suppression to <400 copies/mL at 24 weeks, or ART efficacy, on the given regimen. Abbreviations: ART, antiretroviral therapy; WT, wild-type.
Commission on Macroeconomics and Health, we considered a strategy "very cost-effective" if its ICER was <1 times the per capita gross domestic product (GDP = US$7100 for South Africa in 2010), and "cost effective" if <3 times the GDP [9, 10] . A strategy was "dominated" if it was less effective and costlier than the comparator strategy [11] .
Model Structure
The Cost-Effectiveness of Preventing AIDS Complications (CEPAC)-International Model is a state-transition model of HIV infection that simulates disease progression and clinical care in resource-limited settings using country-specific data [12] (Supplementary Appendix). In the model, HIV-infected individuals are simulated individually from the beginning of HIV care until death. In each month, hypothetical individuals can move between health states including chronic HIV infection, acute clinical events (eg, opportunistic diseases or medication toxicities), and death from both HIV-related and HIVunrelated causes. CD4 count, prophylaxis against opportunistic infection, and history of opportunistic infections determine the risk of these clinical events [13] .
In the model, effective ART leads to suppression of HIV RNA, an increase in CD4 count, and decreased risks for clinical events, as well as an additional, CD4-independent reduction in risk of opportunistic diseases and chronic AIDS death [14, 15] . ART efficacy represents virologic suppression to <400 copies/mL at 24 weeks. Modeled virologic failure can occur either "early" (≤24 weeks) or "late" (>24 weeks) after ART initiation. When virologic failure occurs, HIV RNA rises and CD4 count declines [16] . Consistent with ART guidelines [1, 6] , we modeled individual clinic visits every 3 months, with CD4 count and HIV RNA measured every 6 months. In the model, we simulated 2-lines of sequential ART, NNRTIbased first-line ART and PI-based second-line ART; individuals who fail second-line ART continue on this regimen [6] . ART switching relies on the observation of confirmed and persistent virologic failure (2 consecutive clinic visits with >1 log increase in HIV RNA) in both strategies.
Model Input Parameters
Initialization Cohort: ART Initiation to Failure of First-line ART Characteristics of the ART-naive population were drawn from published reports from South Africa [13, 17, 18] ; mean age was 33 years, 55% were male, mean CD4 count was 73/μL, and median HIV RNA was 4.9 log copies/mL. First-line ART efficacy was 75% [19] (Supplementary Appendix).
Main Analysis: After Failure of First-line ART Cohort Characteristics. At the conclusion of the initialization analyses (when patients failed first-line ART) the cohort mean age was 38.1 years, consistent with prior reports [20] . In the base case, mean CD4 count was 173/μL, and 20% had WT virus [20, 21] (Table 1) .
ART Efficacy. The type and efficacies of ART regimens modeled after first-line ART failure differed among the 4 modeled cohorts (Figure 1 ):
No genotype (PI-based ART only): For the No Geno WT cohort, PI-based ART efficacy was modeled as 60%. For the No Geno Resistant cohort, PI-based ART efficacy was 80% [22] . Modeled PI efficacy was lower among the No Geno WT cohort (60%) than the No Geno Resistant cohort (80%), because we assumed nonadherence as the cause of ART failure in those with WT virus.
Genotype (NNRTI-or PI-based ART): In the Geno WT cohort, following a routine adherence intervention, patients continued NNRTI-based ART with an efficacy of 45% [20] . We modeled this efficacy as lower than that of NNRTI-based ART among treatment-naive patients (75%, see "initialization cohort" above) assuming prior ART nonadherence. In the Geno WT cohort, persistent virologic failure on continued NNRTI-based ART led to a switch to PI-based second-line ART. We assigned an efficacy of 60% to PI-based ART in the Geno WT strategy, lower than the efficacy of PI-based ART in the Resistant cohorts. This was to account for time-dependent selection of NRTI resistance on the "second-chance" on firstline ART. In the Geno Resistant cohort, patients switched to PI-based second-line ART with an efficacy of 80% (equal to the efficacy of PI-based second-line ART in the No Geno Resistant cohort) [22] .
For all regimens and cohorts, individuals on ART with virologic suppression had a modeled increase in CD4 cells of 148/μL at week 24 [23] and 1.3% monthly probability of "late" failure [24] [25] [26] .
Costs. Costs of HIV-related care were derived from HIVinfected cohorts from South Africa (Table 1 and Supplementary Appendix Table 1 ). We converted South African rand (R) to 2010 USD using the South African 2010 mean exchange rate (7.33R = 1USD) and South African GDP deflators [9, 27] . Since adherence counseling is generally part of routine HIV care, the costs of counseling for individuals with detected WT virus in the genotype cohorts were considered part of routine care costs. Costs of ART were derived from public sector sources (Table 1) [2] . Genotype drug resistance testing was $300 per test (Toga Laboratories, personal communication, 5 August 2011).
Sensitivity Analyses. We performed broad univariate analyses and multiway sensitivity analyses, guided by national recommendations, which examined the impact of simultaneous variations in the parameters with the greatest effect on results [8] . Although not currently available in the South African ART rollout, we modeled available third-line ART as Distribution of initial CD4, cells/µL, mean ± SD 173 ± 25 [20, 21] Median HIV RNA, log 10 copies/mL 4.9 [18] Prevalence of WT virus at first-line ART failure 20% (1%-30%) [21] Natural history of disease Mean monthly CD4 decline, cells/µL, by HIV RNA stratum [40] >30 000 copies/mL 6.4
10 001-30 000 copies/mL 5.4
3001-10 000 copies/mL 4.6 501-3000 copies/mL 3.7 0-500 copies/mL 3.0 Efficacy is modeled as the proportion with HIV RNA <400 copies/mL at week 24. c In the base case, there is a 3-month genotype-associated delay in ART switching and a 5% absolute decrease in ART efficacy per 3-month delay (or 1.67% decrease per month) while remaining on a failing regimen. Therefore in the Geno WT cohort, the efficacy of continued NNRTI-based ART in the base case is 40% at 3 months, and in the Geno Resistant cohort, the efficacy of PI-based ART is 75% at 3 months. d Third-line ART: modeled to be available only in sensitivity analyses.
etravirine, darunavir/ritonavir, and raltegravir, with a week 48 efficacy of 86% at $254 per month [28, 29] .
RESULTS
Base Case
Cohort-Based Outcomes In no genotype, cohort No Geno WT, life expectancy after first-line ART failure was projected as 93.9 months (115.4 undiscounted months; Table 2 ): (1) prevalence of WT virus at first-line ART failure (base case = 20%): when WT virus was ≥12%, genotype was very cost-effective compared with no genotype; (2) CD4 count at first-line ART failure (base case = 173/μL): when CD4 count was >80/μL, genotype was very cost-effective; (3) genotypeassociated delays in ART switching (base case = 3 months): genotype was very cost-effective when this delay was <5 months, but when the delay was ≥5 months, genotype reduced life expectancy compared with no genotype, making no genotype preferred; (4) efficacy of continued NNRTI-based ART (cohort Geno WT, base case = 45%): genotype was cost-effective when this efficacy was >15%, and very cost-effective at efficacies >17%; (5) efficacy of PI-based second-line ART (cohort Geno WT, base case = 60%): genotype was very cost-effective if the b Cost-effectiveness threshold represents the threshold value where genotype is very cost-effective compared with no genotype. Guided by the World Health Organization, we consider an incremental costeffectiveness ratio <1 times the South Africa per capita gross domestic product as "very cost-effective." c ART failure = 2 consecutive HIV RNA with >1 log increase.
d A strategy is "dominated" if it is less effective and more costly than the comparator strategy.
e ART efficacy expressed as week 24 HIV RNA <400 copies/mL f "Late" failure = monthly probability of virologic failure after 24 weeks on suppressive ART.
g Cost-effectiveness threshold here represents the threshold value where genotype is cost-saving compared with no genotype. A strategy is cost-saving if it imparts more clinical benefit for less money than the comparator strategy.
efficacy of second-line ART was >38%; (6) third-line ART (base case = $254 per month): if third-line ART was available, genotype became cost-saving; (7) monthly probability of "late" ART failure (base case = 1.3%): genotype was very cost-effective if the probability was ≥1% and cost-saving between 0.25% and 0.9%. When the probability was <0.25%, genotype reduced survival, making no genotype the preferred strategy; (8) genotype test cost (base case = $300): genotype was cost-saving when the test cost was <$100, and very cost-effective at costs greater than this. Genotype remained very cost-effective under plausible variations in the costs of second-line ART, routine care, and an adherence intervention for individuals with WT virus (Geno WT) as well as the discount rate (Supplementary Appendix Table 2 ).
Multiway Analyses
Efficacy of Continued NNRTI-Based ART and Prevalence of WT Virus. In 2-way sensitivity analysis, holding the efficacy of continued NNRTI-based ART at 20%, genotype was very cost-effective when prevalence of WT virus was ≥19%, costeffective at 18% (Figure 2) , and dominated by no genotype at <17% (region not displayed on Figure 2 ). When the efficacy of continued NNRTI-based ART was increased to 70%, genotype was very cost-effective when the prevalence of WT virus was ≥8%, and dominated by no genotype when prevalence was <8% (region not displayed on Figure) .
CD4 Count and Genotype-Associated Delays in ART Switching. In a 2-way sensitivity analysis, we varied both CD4 count at first-line ART failure (base case = 173 cells/μL) and genotype-associated delay in ART switching (base case = 3 months; Supplementary Appendix Table 3 ). Higher CD4 counts at first-line ART failure permitted longer genotype-associated delays, while still achieving gains in life expectancy. For example, at a CD4 count of 500/μL, genotype was very cost-effective when the delay was ≤3 months though the survival benefit declined with increasing delay. Lower CD4 counts at first-line ART failure required shorter delays for genotype to remain clinically effective and cost-effective; when CD4 count was 50/μL at failure, genotype improved survival as long as the genotype-associated delay was <2 months, once delay was ≥3 months no genotype was preferred due to this decrease in survival.
Projected Costs of Genotype Testing at First-line ART Failure. Under base case assumptions at 5 years, the cumulative undiscounted cost per person for genotype was $8830 and for no genotype was $9020 (Supplementary Appendix Figure 1 ). Of total HIV costs, genotype testing represented 3%, ART 34%, laboratory monitoring 9%, and all other HIV care costs (eg, cost of clinic visits, opportunistic infection prophylaxis and events, routine care, and death) 54%. Figure 2 . Two-way sensitivity analysis to examine the impact of prevalence of wild-type (WT) virus at first-line antiretroviral therapy (ART) failure and efficacy of continued nonnucleoside reverse transcriptase inhibitor (NNRTI)-based ART on suppressing human immunodeficiency virus RNA to <400 copies/mL at 24 weeks. The vertical axis represents the incremental cost-effectiveness ratio (ICER) of genotype compared with no genotype. The horizontal axis represents the prevalence of WT virus at first-line ART failure. Combinations of efficacy of continued NNRTI-based ART and prevalence of WT virus that yield ICERs above and to the left of the marked efficacy curves represent scenarios where genotype is "dominated" by no genotype, and the horizontal axis extends beyond the 30% mark to represent scenarios where genotype is very cost-effective compared with no genotype. The solid curve represents the base-case efficacy of continued NNRTI-based ART assuming a 3-month genotype-associated delay in care. The shaded gray region represents cases where the ICER of genotype is ≤1 times the South Africa gross domestic product ($7100) and very cost-effective. Circles represent the threshold prevalence of WT virus below which genotype becomes very cost-effective. Abbreviations: ART, antiretroviral therapy; GDP, gross domestic product; ICER, incremental cost-effectiveness ratio; NNRTI, nonnucleoside reverse transcriptase inhibitor; YLS, years of life saved.
DISCUSSION
Effective and efficient management of first-line ART failure in resource-limited settings is critical due to limited availability of ART regimens and relatively higher costs of second-line ART. Several studies have examined the clinical and economic impact of genotype testing in the United States [30, 31] and Europe [32] . While ART rollout has accelerated in resourcelimited settings, there has been limited analysis of the clinical and economic impact of individual genotype testing at firstline ART failure in these settings.
We used a validated simulation model of HIV disease and found that genotype testing at first-line ART failure increased the projected survival of HIV-infected patients by 2.2 months compared to no genotype testing, the current standard of care [6] . This gain in life expectancy is comparable to other HIV-related laboratory monitoring interventions in resourcelimited settings [33] . Average time on PI-based second-line ART was 5 months less in a strategy of genotype testing compared with standard of care. The deferral of a more expensive second-line regimen in patients with persistent WT virus provides clinical as well as economic benefits by continuing less expensive ART in patients who may resuppress with improvement in ART adherence. As a result, genotype testing was very cost-effective compared to switching all patients failing firstline ART to PI-based second-line ART. The benefits of genotype testing persisted even if the reported prevalence of WT virus was reduced by 40% from the modeled base case (from 20% to 12%) or the test costs were >2-fold greater than current estimates (from $300 to $600).
Cost has been a major barrier to the rollout of PI-based second-line ART. Drug-related costs contribute almost threequarters of the expense of second-line ART in South Africa [34] . Recently, the cost of ART has decreased through negotiations with drug manufacturers and approval of generic regimens [35] . The availability of less expensive second-line ART did not affect our main conclusions, consistent with a costconsequence analysis of genotype testing in South Africa [36] . Furthermore, a genotype testing strategy at first-line ART failure may be cost-saving if the test cost were <$100 or thirdline ART were to become available, since the one-time cost of genotype testing is outweighed by ART and other recurring HIV care costs.
The clinical and economic benefits of genotype testing are particularly critical in patients with low CD4 counts at ART failure where genotype results must lead promptly to ART switching. This is consistent with prior reports of the highrisk for serious clinical events and death for patients failing first-line NNRTI-based ART particularly with WT virus [20] . Therefore, program planners should consider operational strategies to reduce delays in processing of the genotype test and delivering results. Individuals with advanced immunosuppression may require immediate switching to potent ART when prompt implementation of genotype test results cannot be assured.
No genotype at first-line ART failure was the preferred strategy when the efficacy of a renewed trial of an NNRTIbased regimen was significantly reduced (≤10%). Such low efficacies with this second chance at NNRTI-based ART, although much lower than reported to date [20] , might result from repeated nonadherence or the selection of drug resistance mutations over time.
This analysis has several limitations. First, model inputs for ART efficacy did not capture information on the relationship between ART adherence and ART efficacy [20, 22] . Second, in resource-limited settings, the effect of viral resistance on the efficacy of PI-based second-line ART has been described infrequently [37] [38] [39] . Third, we derived model inputs for sex distribution from a large observational cohort in South Africa and this assumption may not represent settings where sex-associated rates of adherence differ. To address these issues, we modeled the effect of ART adherence indirectly, through assumptions based on available data ( Figure 1 ) and sensitivity analyses on ART efficacies. Lastly, while clinical and immunologic monitoring is more common than virologic monitoring in resource-limited settings, we modeled a scenario where genotype and viral load technologies were both available, since genotyping is contingent on detectable viremia. However, we addressed the impact of delayed detection of virologic failure by simulating delays in ART switching and lower CD4 counts at first-line ART failure.
In conclusion, we project that genotype testing, performed in settings where the prevalence of WT virus in those failing first-line ART is ≥12% and informing clinical decision-making <5 months from that failure, will improve survival in HIVinfected individuals. The upfront cost of the genotype test is largely offset by the deferral of a more expensive second-line regimen in patients who fail ART due to nonadherence, rendering genotype resistance testing very cost-effective.
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